Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Sorafenib.

Olwen Hahn1, Walter Stadler

  • 1Section of Hematology/Oncology, Department of Medicine, University of Chicago, Illinois 60637, USA.

Current Opinion in Oncology
|September 22, 2006
PubMed
Summary
This summary is machine-generated.

Sorafenib, an oral multikinase inhibitor, demonstrated increased progression-free survival in metastatic renal cell cancer patients. This finding was confirmed in phase III trials, establishing its role in renal cancer treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of a Weight Loss Intervention on 1-Year Weight Change in Women With Stage II/III Breast Cancer: Secondary Analysis of the Breast Cancer Weight Loss (BWEL) Trial.

JAMA oncology·2025
Same author

A randomized phase II trial of nab-paclitaxel with or without mifepristone for advanced triple-negative breast cancer.

Breast cancer research and treatment·2025
Same author

Evaluation of cyclin-dependent kinase 4/6 inhibitor-induced serum creatinine elevations in patients with hormone receptor positive breast cancer.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners·2024
Same author

Retrospective evaluation of adjuvant capecitabine dosing patterns in triple negative breast cancer.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners·2024
Same author

Impact of the COVID-19 Pandemic on Cancer Clinical Trials: Alliance for Clinical Trials in Oncology Experience (Alliance A152022).

Journal of clinical trials·2024
Same author

Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma.

The New England journal of medicine·2024
Same journal

Artificial intelligence-augmented robotic surgery in gynecologic oncology: intraoperative assistance and analytics.

Current opinion in oncology·2026
Same journal

Artificial intelligence in cervical cancer screening and triage: a role-stratified systematic review and bivariate meta-analysis.

Current opinion in oncology·2026
Same journal

Deep learning assisting the surgical management of gynecologic cancers.

Current opinion in oncology·2026
Same journal

Pain management in pancreatic cancer: time to change our strategy!

Current opinion in oncology·2026
Same journal

Systemic radionuclide treatments in gastro-entero-pancreatic neuroendocrine tumours.

Current opinion in oncology·2026
Same journal

5-Fluorouracil at seventy: still attractive but barely understood. A cautionary tale for drug development.

Current opinion in oncology·2026
See all related articles

Area of Science:

  • Oncology
  • Pharmacology
  • Clinical Trials

Background:

  • Sorafenib is an oral multikinase inhibitor approved for metastatic renal cancer.
  • It targets multiple tyrosine kinases, including VEGFR and PDGFR, and Raf kinase.
  • Investigational use extends to locally advanced renal cancer and other tumor types.

Purpose of the Study:

  • To review the clinical development of sorafenib.
  • To discuss its role in treating renal cancer.
  • To highlight clinical trial design and biomarker development.

Main Methods:

  • Phase II randomized discontinuation trial to assess clinical benefit.
  • Phase III international trial to confirm phase II findings.
  • Review of clinical development and trial methodologies.

Related Experiment Videos

Main Results:

  • Sorafenib demonstrated prolonged disease stabilization in early trials.
  • A phase II trial showed increased progression-free survival in metastatic renal cell cancer.
  • Phase III trials confirmed these positive outcomes.

Conclusions:

  • Sorafenib has a significant role in the treatment of renal cancer.
  • Effective clinical trial design and biomarker development are crucial for drug advancement.
  • Further research into sorafenib's application in various cancers is ongoing.